News Feed Comments

Press Release – GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder

RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY) for Vyvanse(R), to help improve the recognition and treatment of adult

Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adult Attention Deficit, Adult Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity, Attention Deficit Hyperactivity Disorder, Cii, Deficit Hyperactivity Disorder, Firstcall, Glaxosmithkline, Glaxosmithkline Plc, Gsk, Hyperactivity, Nasdaq, Nyse, Prnewswire, Promotion Agreement, Research Triangle Park, Shp, Shpgy, Triangle Park, Vyvanse

Footer #1 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #2 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #3 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #4 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

© 2010 VyvanseInfo.com · Streamline theme by StudioPress · Get a Blog · WordPress · Log in